Why TherapeuticsMD Is Skyrocketing
TherapeuticsMDwas leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials.
TherapeuticsMDwas leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials.
Onconova Therapeutics led the bulls early in Tuesday’s trading session on positive data from an ongoing Phase 1/2 clinical trial.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Bluebird Bio absolutely tanked in Monday's trading session, based on preclinical and manufacturing data from the American Society of Hematology Annual Meeting.
Threshold Pharmaceuticals watched its stock completely collapse in Monday’s session after a joint late-stage study failed to yield positive results.
Idera Pharmaceuticals made a strong push in Monday’s session following the presentation of its clinical data over the weekend.
MEI Pharma Inc. (NASDAQ: MEIP) was leading the bulls in the broad markets Monday on news of positive Phase 2 results. The company announced positive results from a study of its investigational drug candidate…
These biotech companies stood out from the rest with incredible gains or losses over the course of the past week.
KaloBios Pharmaceuticals continues to vastly outperform the broad markets through December after Martin Shkreli took the helm.
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) was leading the bulls early in Thursday’s session on positive results from a Phase 2 study. The company announced positive top-line results from its Phase 2 clinical study of…
Rite Aid reported its sales results for its retail pharmacy segment for the month of November before the markets opened Thursday.
Medtronic reported better-than-expected fiscal second-quarter financial results before the markets opened on Thursday.
Medtronic is scheduled to report its fiscal second-quarter financial results after the markets close on Thursday.
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
InVivo Therapeutics announced a new strategy for the treatment of chronic spinal cord injury.